We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Diabetes

Journal Scan / Research · November 30, 2017

Risks of Cardiovascular Events and Mortality Are Lower With Dapagliflozin Than With DPP-4 Inhibitors

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Dapagliflozin Is Associated With Lower Risk of Cardiovascular Events and All-Cause Mortality in People With Type 2 Diabetes (CVD-REAL Nordic) When Compared With Dipeptidyl Peptidase-4 Inhibitor Therapy: A Multinational Observational Study
Diabetes Obes Metab 2017 Sep 08;[EPub Ahead of Print], F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, M Thuresson, P Fenici, D Nathanson, JW Eriksson, A Norhammar, J Bodegard, KI Birkeland

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading